Electroporation promotes HtrA1 uptake and in a mouse model of mesothelioma

Frontiers in Bioscience - Elite

Volumn 5 E, Issue 3, 2013, Pages 974-981

  Spugnini, Enrico P ^a   Cardillo, Irene ^a   Fanciulli, Maurizio ^a   Crispi, Stefania ^b   Vincenzi, Bruno ^c   Boccellino, Mariarosaria ^d   Quagliuolo, Lucio ^d   Baldi, Alfonso ^d  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Biphasic pulses; CDDP; Electrochemotherapy; HtrA1; Mesothelioma; Xenograft

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; HTRA1 PROTEIN; UNCLASSIFIED DRUG; PRSS11 PROTEIN, MOUSE; SERINE PROTEINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SIZE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG PENETRATION; ELECTROPORATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MALIGNANT MESOTHELIOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR RECURRENCE; ANIMAL; GENETICS; MESOTHELIOMA; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; ELECTROPORATION; HUMANS; MALE; MESOTHELIOMA; MICE; MICE, NUDE; SERINE ENDOPEPTIDASES;

EID: 84884324801     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Grondin S, Sugarbaker D. Malignant mesothelioma of the pleural space. Oncology 13, 919-926 (1999)
2. Price B, Ware A. Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology and End Results Program data from 1973 through 2003. Am J Epidem 2, 107-112 (2004)
3. Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer 79, 666-672 (1999)
4. Bouten C, Schlesser M, Frenay C, Asteoul P. Malignant pleural mesothelioma. Eur Respir J 12, 972-981 (1998)
5. Ramos-Nino ME, Testa JR, Altomare DA, Pass HI, Carbone M, Bocchetta M, Mossman BT. Cellular and molecular parameters of mesothelioma. J Cell Biochem 98, 723-734 (2006)
6. Spugnini EP, Bosari S, Citro G, Lorenzon I, Cognetti F, Baldi A. Human malignant mesothelioma: molecular mechanisms of pathogenesis and progression. Int J Biochem Cell Biol 38, 2000-2004 (2006)
7. Mossman BT, Gee J. Asbestos related diseases. N Engl J Med 320, 1721-1730 (1989)
8. Mossman BT, Churg A. Mechanisms in the pathogenesis of asbestosis and silicosis. Am J Respir Crit Care Med 157, 1666-1680 (1998)
9. Selikoff IJ, Hammond EC, Seidman H. Latency of asbestos disease among insulation workers in the United States and Canada. Cancer 46, 2736-2740 (1980)
10. De Luca A, Baldi A, Esposito V, Howard CM, Bagella L, Rizzo P, Caputi M, Pass HI, Giordano GG, Baldi F, Carbone M, Giordano A. The retinoblastoma gene family pRb/p105, p107, pRb2/p130 and simian virus-40 large Tantigen in human mesotheliomas. Nature Med 3, 913-916 (1997)
11. Carbone M, Fisher S, Powers A, Pass HI, Rizzo P. New molecular and epidemiological issues in mesothelioma: role of SV40. J Cell Physiol 180, 167-172 (1999)
12. Rizzo P, Carbone M, Fisher SG, Matker C, Swinnen LJ, Powers A, Di Resta I, Alkan S, Pass HI, Fisher RI. Simian virus 40 is present in most United States human mesotheliomas, but it is rarely present in non-Hodgkin's lymphoma. Chest 116(S), 470-473 (1999)
13. Lo MMS, Tsong TY, Conrad MK, Strittmatter SM, Hester LD, Snyder SH: Monoclonal antibody production by receptor-mediated electrically induced cell fusion. Nature 31, 792-794 (1984)
14. Orlowski S, Belehradec J, Paoletti C, Mir LM: Transient electropermeabilization of cells in culture. Increase of the cytotoxicity of anticancer drugs. Biochem Pharmacol 37, 4727-4733 (1988)
15. Fromm M, Taylor LP, Walbot V: Expression of genes transferred into monocot and dicot plant cells by electroporation. Proc Nat Acad Sci USA 82, 5824-5828 (1985)
16. Poddevin B, Orlowski S, Belehradek J Jr, Mir LM: Very high cytotoxicity of bleomycin introduced into the cytosol of cells in culture. Biochem Pharmacol 42(Suppl), 67-75 (1991)
17. Belehradek M, Domenge C, Luboinski B, Orlowski S, Belehradek J Jr, Mir LM: Electrochemotherapy, a new antitumor treatment. First clinical phase I-II trial. Cancer 72, 3694-3700 (1993)
18. Rudolf Z, Stabuc B, Cemazar M, Miklavcic D, Vodovnik L, Sersa G: Electrochemotherapy with bleomycin. The first clinical experience in malignant melanoma patients. Radiol Oncol 29, 229-235 (1995)
19. Keller R, Jaroszeski M, Glass FL, Messina JL, Rapaport DP, DeConti RC, Fenske NA, Gilbert RA, Mir LM, Reintgen DS: Phase I/II trial for the management of cutaneous and subcutaneous tumors using electrochemotherapy. Cancer 77, 964-971 (1996)
20. Daskalov I, Mudrov N, Peycheva E: Exploring new instrumentation parameters for electrochemotherapy. IEEE Eng Med Biol Mag 18, 62-66 (1999)
21. Spugnini EP, Dotsinsky I, Mudrov N, Citro G, D'Avino A, Baldi A: Biphasic pulses enhance bleomycin efficacy in a spontaneous canine genital tumor model of chemoresistance: Sticker sarcoma. J Exp Clin Cancer Res 27, 58 (2008)
22. Spugnini EP, Porrello A: Potentiation of chemotherapy in companion animals with spontaneous large neoplasms by application of biphasic electric pulses. J Exp Clin Cancer Res 22, 571-580 (2003)
23. Spugnini EP, Vincenzi B, Baldi F, Citro G, Baldi A: Adjuvant electrochemotherapy for the treatment of incompletely resected canine mast cell tumors. Anticancer Res 26, 4585-4589 (2006)
24. Spugnini EP, Baldi A, Vincenzi B, Bongiorni F, Bellelli C, Porrello A: Intraoperative versus postoperative electrochemotherapy in soft tissue sarcomas: a preliminary study in a spontaneous feline model. Cancer Chemother Pharmacol 59, 375-381 (2007)
25. Spugnini EP, Vincenzi B, Citro G, Santini D, Dotsinsky I, Mudrov N, Montesarchio V, Laieta MT, Esposito V, Baldi A: Adjuvant electrochemotherapy for the treatment of incompletely excised spontaneous canine sarcomas. In Vivo 21, 819-822 (2007)
26. Spugnini EP, Baldi F, Mellone P, Feroce F, D'Avino A, Bonetto F, Vincenzi B, Citro G, Baldi A: Patterns of tumor response in canine and feline cancer patients treated with electrochemotherapy: preclinical data for the standardization of this treatment in pets and humans. J Transl Med 5, 48 (2007)
27. Spugnini EP, Citro G, Mellone P, Dotsinsky I, Mudrov N, Baldi A: Electrochemotherapy for localized lymphoma: a preliminary study in companion animals. J Exp Clin Cancer Res 26, 343-346 (2007)
28. Peycheva E, Daskalov I, Tsoneva I: Electrochemotherapy of Mycosis fungoides by interferonalpha. Bioelectrochemistry 70, 283-286 (2007)
29. Mennuni C, Calvaruso F, Zampaglione I, Rizzuto G, Rinaudo D, Dammassa E, Ciliberto G, Fattori E, La Monica N: Hyaluronidase increases electrogene transfer efficiency in skeletal muscle. Hum Gene Ther 13, 355-365 (2002)
30. Zaharoff DA, Barr RC, Yuan F: Electromobility of plasmid DNA in tumor tissues during electric fieldmediated gene delivery. Gene Ther 9, 1286-1290 (2002)
31. Chien J, Aletti G, Baldi A, Catalano A, Muretto P, Keeney GL, Kalli KR, Staub J, Ehrmann M, Cliby WA, Lee JK, Bible KC, Hartmann LC, Kaufmann SH, Shridhar V. Serine proteae HtrA1 modulates chemotherapy-induced cytoxicity. J Clin Invest 116, 1994-2004 (2006)
32. Baldi A, Mottolese M, Vincenzi B, Campioni M, Mellone P, Di Marino MP, Di Crescenzo V, Visca P, Menegozzo S, Citro G, Cerebelli A, Mirri A, Chien J, Shridhar V, Ehrmann M, Santini M, Facciolo F. The serine protease HtrA1 is a novel prognostic factor for human mesothelioma. Pharmacogenomics 9, 1069-1077 (2008)
33. Baldi A, De Luca A, Morini M, Battista T, Felsani A, Baldi F, Catricalà C, Amantea A, Noonan DM, Albini A, Natali PG, Lombardi D, Paggi MG. The HtrA1 serine protease is down-regulated during human melanoma progression and represses growth of metastatic melanoma cells. Oncogene 21, 6684-6688 (2002)
34. Spugnini EP, Citro G, Porrello A: Rational design of new electrodes for electrochemotherapy. J Exp Clin Cancer Res 24, 245-254 (2005)
35. De Luca A, De Falco M, Severino A, Campioni M, Santini D, Baldi F, Paggi MG, Baldi A. Distribution of the serine protease HtrA1 in normal human tissues. J Histochem Cytochem 51, 1279-1284 (2003)
36. De Luca A, De Falco M, De Luca L, Penta R, Shridhar V, Baldi F, Campioni M, Paggi MG, Baldi A. Pattern of expression of HtrA1 during mouse development. J Histochem Cytochem 52, 1609-1617 (2004)
37. De Luca A, De Falco M, Fedele V, Cobellis L, Mastrogiacomo A, Laforgia V, Tuduce IL, Campioni M, Giraldi D, Paggi MG, Baldi A. The serine protease HtrA1 is upregulated in the human placenta during pregnancy. J Histochem Cytochem 52, 885-892 (2004)
38. Rush VW, Piantadosi S, Holmes EC. The role of extrapleural pneumonectomy in malignant pleural mesothelioma; A Lung Cancer Study Group trial. J Thoracic Cardiovasc Surg 102, 1-9 (1991)
39. Grondin SC, Sugarbaker DJ. Pleuropneumonectomy in the treatment of malignant pleural mesothelioma. Chest 116, 450S-454S (1999)
40. Boutin C, Rey F, Viallat JR. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma: a randomized trial of local radiotherapy. Chest 108, 754-758 (1995)
41. Rusch VW, Rosenzweig K, Venkatraman E, Leon L, Raben A, Harrison L, Bains MS, Downey RJ, Ginsberg RJ. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 122, 788-795 (2001)
42. Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, DeCamp MM Jr, Swanson SJ, Bueno R, Lukanich JM, Baldini EH, Mentzer SJ. Resection margins, extrapleural nodal status, and cell type determine postoperative long-Term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 117, 54-65 (1999)
43. Baas P. Chemotherapy for malignant mesothelioma: from doxorubicin to vinorelbine. Semin Oncol 29, 62-69 (2002)
44. Steele JPC, Klabatsa A. Chemotherapy options and new advances in malignant pleural mesothelioma. Ann Oncol 16, 345-351 (2005)
45. Mikulski SM, Costanzi JJ, Vogelzang NJ, McCachren S, Taub RN, Chun H, Mittelman A, Panella T, Puccio C, Fine R, Shogen K. Phase II trial of a single weekly intravenous dose of rapirnase in patients with unresectable malignant mesothelioma. J Clin Oncol 20, 274-281 (2002)
46. Destro A, Ceresoli GL, Falleni M, et al. EGFR overexpression in malignant plerural mesothelioma: an immunohistochemical and molecular study with clinicopathological correlations. Lung Cancer 51, 207-215 (2006)
47. Topuz E, Saip P, Aydiner A, Salihoglu Y, Aydin Y, Topuzlu C. Catheter complications associated with intraperitoneal chemotherapy. Eur J Gynaecol Oncol 19, 275-279 (1998)
48. Du KL, Both S, Friedberg JS, Rengan R, Hahn SM, Cengel KA. Extrapleural pneumonectomy, photodynamic therapy and intensity modulated radiation therapy for the treatment of malignant pleural mesothelioma. Cancer Biol Ther 10, 425-429 (2010)
49. Barbetakis N, Asteriou C, Papadopoulou F, Samanidis G, Paliouras D, Kleontas A, Lyriti K, Katsikas I, Tsilikas C. Early and late morbidity and mortality and life expectancy following thoracoscopic talc insufflation for control of malignant pleural effusions: a review of 400 cases. J Cardiothorac Surg 5, 27 (2010)